Rapport Therapeutics, Inc. (RAPP)
34.68
-0.53
(-1.51%)
USD |
NASDAQ |
Jun 11, 09:47
Rapport Therapeutics SG&A Expense (Quarterly) : 11.50M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 11.50M |
| December 31, 2025 | 8.251M |
| September 30, 2025 | 7.707M |
| June 30, 2025 | 6.816M |
| March 31, 2025 | 7.536M |
| December 31, 2024 | 6.322M |
| September 30, 2024 | 6.097M |
| Date | Value |
|---|---|
| June 30, 2024 | 5.111M |
| March 31, 2024 | 4.59M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 1.909M |
| March 31, 2023 | 1.292M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| EyePoint, Inc. | 15.25M |
| Biofrontera, Inc. | 11.00M |
| ANI Pharmaceuticals, Inc. | 73.66M |
| Corcept Therapeutics, Inc. | 145.36M |
| Assertio Holdings, Inc. | 11.14M |